Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109080 | 0.82 | CYSLTR2 (0.46) | PTGDR2CYP1A2MAPTCYSLTR1CYSLTR2 | |
| SCHEMBL5105338 | 0.78 | CYP1A2 (0.40) | PTGDR2CYP1A2AKR1B1CYSLTR1CYSLTR2 | |
| SCHEMBL5106908 | 0.78 | CYSLTR1 (0.46) | PTGDR2AKR1B1CYSLTR1CYSLTR2GPBAR1 | |
| SCHEMBL5120863 | 0.75 | PPARG (0.40) | PTGDR2CYP1A2AKR1B1CYSLTR1CYSLTR2 | |
| SCHEMBL12584503 | 0.74 | NOD2 (0.64) | SMN1; SMN2POLBTDP1MAPTCYSLTR1 | |
| SCHEMBL5120280 | 0.71 | CYSLTR1 (0.50) | PTGDR2MAPTAKR1B1CYSLTR1CYSLTR2 | |
| SCHEMBL5106653 | 0.70 | SMN1; SMN2 (0.49) | SMN1; SMN2POLBTDP1CYP1A2RAB9A | |
| SCHEMBL3615800 | 0.69 | NOD2 (0.52) | SMN1; SMN2POLBPTGDR2TDP1MAPT | |
| SCHEMBL28553196 | 0.68 | KDM4E (0.46) | SMN1; SMN2POLBTDP1CYP1A2L3MBTL1 | |
| SCHEMBL5112901 | 0.68 | CYSLTR1 (0.53) | CYSLTR1CYSLTR2GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | SMN1; SMN2 3876/4885POLB 4079/4885PTGDR2 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.